臺灣博碩士論文加值系統

慢性胰臟炎導因於長期的發炎終以致胰臟內分泌與外分泌功能的缺失。所以，慢性胰臟炎可說是一種在形態上有不可逆的變化以及功能上有不可回復性的一種疾病，這也就是慢性胰臟炎臨床上(或功能上)的定義。慢性胰臟炎的進展迵異，可能經過十數或數十年才慢慢地導致嚴重的臨床症狀或是也可能在短時間內即進展很迅速。典型慢性胰臟炎的病理表現為胰臟組織外分泌細胞的破壞與纖維化，在組織分析上，也可見到胰管內可能有蛋白質塊沈積、胰管內結石、胰管擴張、或胰管增生或化生以及偽囊腫的發現，這些病理學的診斷通常必須經由足夠的檢體，通常來自於外科手術所取得的檢體或是解剖的組織病理檢體才足以下診斷。並且這些纖維化及病理學的變化可能不均勻地分佈在其中。在同一個胰臟不同的部位其發炎程度可能並不平均。

在過去的數十年間，有許多學者嘗試想要對於慢性胰臟炎建立一個簡單且清楚的定義與分類。先前的幾種分類法，幾乎都是各唱各的調，多半源自臨床表徵的觀察，而缺乏系統性且簡單的分類。，慢性胰臟炎的診斷與分類應兼具原因、胰臟功能和臨床表現型。Whitcomb提出針對慢性胰臟炎的原因與風險做一個評估系統的分析: TIGAR-O system，建議對每一個懷疑或被診斷為慢性胰臟炎的病人，要列出所有可能的危險因子，並且根據這些因子和臨床表現之間的相關性，希望能對其發生的原因做更進一步的了解。所謂的TIGAR-O系統，就是toxic、metabolic、genetic、autoimmune、recurrent severe pancreatitis以及obstructive chronic pancreatitis。至此在不同的時代背景不同的地域所提出的特殊型態的慢性胰臟炎，似乎都可納入在此TIGAR-O系統當中。此系統的提出在背後的更重要意涵是我們可以經由致病機轉了解慢性胰臟炎，藉此幫助病人臨床病程之追蹤與治療。
慢性胰臟炎的發生率和其流行病學的研究，事實上資料相當有限，主要的原因在於慢性胰臟炎並不屬於惡性疾病，所以在絕大多數的國家並沒有慢性胰臟炎的登記系統。再者由於慢性胰臟炎的診斷與定義並不清楚與明確，所以大多數人對於急性與慢性定義或分類之混淆或不了解對於胰臟發炎的基本觀念已有很大的轉變，所以想得到慢性胰臟炎之可靠資訊可說是十分困難。目前認為可能可信的資訊是來自於對於治療胰臟疾病有經驗的醫學或研究中心。 至於想要了解其致病原因及分析流行病學，就會牽涉到如何對慢性胰臟炎下診斷：最可靠的方法是根據組織病理(足夠的標本通常是外科組織標本)，但是這在臨床上並不常使用，此外診斷標準的界定也會影響到流行病學調查結果的不同。最後則是在不同的地域國家，發生慢性胰臟炎的原因也可能不同。

慢性胰臟炎目前並沒有任何特效藥，所以希望藉由對發病原因與風險的評估，以期對這些病人的將來與預後和治療能有幫忙。如果我們回顧過去這一百年來有關慢性胰臟炎的研究，就可以發現1996年是一個重要的分水嶺，也就是開始發現基因和胰臟炎相關的時代，因為在1996年之前所有的研究都是分析其臨床病理的表現，在1996年之後發現cationic trypsinogen gene (PRSS1)和cystic fibrosis transmembrane conductance(CFTR)與慢性胰臟炎之發生相關。愈來愈多證據顯示不同原因別的慢性胰臟炎似乎都與這些基因有不同程度的相關，是所謂慢性胰臟炎的基因時代。

本研究共分三部份

第一部份是慢性胰臟炎的臨床資料整理，重新審視與分類
第二部分是不明原因慢性胰臟炎與CFTR 和tumor necrosis factor(TNF)-alpha promoter之基因關聯研究
第三部分是嘗試找出鑑別慢性胰臟炎與胰臟癌之生物標記。


慢性胰臟炎在台灣的資料，到目前都沒有正式的報告，對於慢性胰臟炎的原因別和分類，病人的臨床病理資料等等，也都十分的缺乏。至於慢性胰臟炎在中國人種的基因背景在之前也沒有任何的文獻報告。所以我們研究的目標主要是分析台灣華人或在台灣的中國人慢性胰臟炎的臨床病理特徵分析，並嘗試以新的分類方式對比舊的分類方式來分析。第二部分則是有關慢性胰臟炎的基因研究。


我們嘗試用兩個不同資料庫來分析慢性胰臟炎在中國人或台灣華人的情形，在這十二年間，也就是民國83-94年間每一年新發生慢性胰臟炎的個案數，其實並沒有明顯的上升或減少，對照目前西方的報告來看，他們也認為慢性胰臟炎個案的總數目前可能是持平的，這一點和國外的報告相近。至於在性別方面不論是源自病歷資料庫或是病理資料庫我們都可以發現病人都是以男生為多，女生較少。如果我們逐年來看發生慢性胰臟炎的原因，我們可以發現喝酒不論臨床或病理上都佔有蠻大的比例。而不明原因慢性胰臟炎在病理資料庫當中所佔的比例似乎有逐年上升趨勢，已經是慢性胰臟炎在台灣的主要或次要原因。

本研究的第二部分我們想了解的是慢性胰臟炎的基因背景，我們嘗試由兩種方面的基因來著手: CFTR和西方人發生不明原因慢性胰臟炎有關，是一個非常重要的基因;TNF-alpha則是和胰臟纖維化與發炎反應有關。
WHO定義CFTR基因變異的單一表現型中包括了慢性胰臟炎。CFTR的功能本身是一種氯離子通道，它可以調控上皮細胞內外兩側的HCO3-、氯離子和水的平衡。CFTR基因大約有230 kb，蛋白質由1480個氨基酸組成。CFTR protein的表現會受到CFTR基因變異程度的影響。CFTR的基因變異和胰臟功能之間的關係亦即其基因型-表現型之間的相關性最高。CFTR和不明原因慢性胰臟炎之間有相關的首次發表是在1998年同時在NEJM發表的兩篇文章。所以我們收集了2000-2005年在台大醫院確定診斷為慢性胰臟炎的病人，當中48位男性，30位女性，200個對照組的病人，分析 CFTR的變異和基因多型性以及配子型分析研究。CFTR是人類已知的基因當中，基因型非常複雜的基因，所以目前都推薦以DHPLC來做。所以我們將CFTR 27個exon包括intron用PCR的方法放大，並且以DHPLC分析 ，如果得到異常結果再做進一步的核酸定序分析。並且分析的結果都與目前CFTR變異資料庫來做核對。除了變異之外，CFTR變異會受到轉譯或轉錄層次調控。對於目前已知有功能性的基因多型性，我們直接進行了核酸定序的方法來分析，進一步看他們的基因型與表現型之間之相關，此外也進一步做配合子的分析。
本研究也是首次有關於華人慢性胰臟炎之發生與CFTR相關的報告。這是一個病例對照研究，在不明原因慢性胰臟炎患者中，CFTR的對偶基因突變率為14.1﹪，在對照組為4.8﹪，不明原因慢性胰臟炎患者中有24.4﹪具有CFTR突變，對照組有9.5﹪。根據我們的研究，具有CFTR異常對偶基因的帶原者（carrier），發生慢性胰臟炎的機會為對照組的9倍。CFTR的突變分布比較廣散，在某些變異的點位只出現在慢性胰臟炎的病人，在對照組的病人並沒有變化。在所有的突變當中以I556發生率最高。分析基因型與表現型的相關時，我們發現具有5T的對偶基因的患者其發生不明原因慢性胰臟炎的年齡較輕，這些CFTR carrier的poly TG repeat 數目均為12或13。我們對於6個已知有功能上影響的基因多型性位址，組成配合子進一步分析。包括了125G1C，100/T11C>T，M470V，2694T>G，4521G>A而經由permutation test發現在中國人CFTR最常見的配合子型有13種，當中以 125C /1001+11C/ T7TG12/470M/2694T /4521G 的配合子最常見。而125G/100/T11C/TG12/470M/2694T/4521G的配合子型和中國人發生不明原因慢性胰臟炎的相關性最高（OR 11.3，95﹪信賴區間為2.5-54.6）。

本研究顯示出不同地域與人種和CFTR基因變化有很大之不同。因此針對CFTR知基因篩檢時，應就族群之不同而分別訂定。本研究建立了中國人CFTR基因在不明原因慢性胰臟炎與正常人變化的基因資料庫，對於未來其他與CFTR相關之疾病之背景與資料庫建立特定表現型（例如CF，不明原因慢性胰臟炎，與CABVD）提供了一個重要的資訊。


許多慢性發炎性疾病均和TNF-alpha有關。至於TNF-alpha和慢性胰臟炎之間是否有相關，我們發現在以往歐洲和美國的報告呈現不一致，這可能導因於先前所收案的研究中的族群不夠均質化，或者也部份源自於地域人種的不同。至於TNF-alpha的基因多型性，和中國人或台灣華人的慢性胰臟炎有沒有相關，相當值得進一步的研究。本論文總共收集70個慢性胰臟炎病人，其中48位男性，22個女性以及200個對照組。在此病例對照研究中，病人的年齡和性別都沒有統計學上的差異。我們排除了遺傳型的胰臟炎有關的情形，合併胰臟癌的病人也排除在外。我們的結果顯示TNF863，CA或AA的基因型，和我們族群慢性胰臟炎的發生最為相關，其OR為4.919（p值小於0.001），如果我們以單一的基因多型性來分析，我們發現863A或103C的帶原者都和病人慢性胰臟炎的發生最為相關，具有統計學上的差異。配子型如果按照1031/863/857/308/238的排列， TACAG ，CATGG和CACAG和中國人的慢性胰臟炎發生最為相關。我們的結果顯示出TNF-alpha與中國人慢性胰臟炎之發生相關性存在，在TNF-alpha promoter的863A或者是含有863A的配合子和慢性胰臟炎發生的相關性最高。至於TNF-alpha在整個胰臟炎形成之中扮演什麼樣的角色，值得未來繼續研究。
慢性胰臟炎已被認為是罹患胰臟癌的高危險族群。根據不同於原因引起的慢性胰臟炎其得到胰臟癌的風險亦不同，例如具有遺傳性慢性胰臟炎之患者終生的到胰臟癌的機會為40﹪，其風險是一般人的數十至數百倍，而酒精性慢性胰臟炎得到胰臟癌的風險是一般人的四倍。其他不同類別的慢性胰臟炎得到胰臟癌的機會也是正常人之2倍。當慢性胰臟炎的病人出現其胰臟出現局部腫大時，有時在臨床上並無不同的症狀。所以，如何鑑別特定病人的胰臟局部腫大，是慢性發炎所導致的假腫瘤，或是已併發胰臟癌，是很重要的臨床問題。相反地，對於某些確實患有慢性胰臟炎的病人，可能也會因為腫瘤源起於或壓迫到主胰管，而使得其後方之胰管擴張，而引起胰臟慢慢萎縮。發展出準確度和敏感度較佳的非侵襲性生物標記，是胰臟研究一直以來的方向與目標。
最傳統或最常使用的指數是CA19-9，通常是用在胰臟癌病人治療過程中追蹤他們的治療效果。但是，是否CA19-9可以用來當作區分胰臟癌或者是慢性胰臟炎的指標則到目前仍未有定論。此外，CA19-9在一些慢性發炎的疾病或包括慢性肝炎，腎功能不好或是慢性胰臟發炎或病人有任何原因的黃疸，都可以使得CA19-9指數假性上升。反過來說，在人口中約有百分之十左右的病人並不表現lewis antigen，所以他們即使他們發生了胰臟癌，他們的CA19-9指數也不會上升。依照以往文獻的報告想要用CA19-9來區分慢性胰臟炎或者是胰臟癌，正確率大約只有六成左右，因為大約有百分之四十左右的病人，他們的CA19-9可能已經上升。其他的腫瘤標記，譬如說CEA，CA-242，CA-50，CA-724等都被嘗試拿來作為診斷胰臟癌，但是可惜這些腫瘤標記的特異性和敏感性均不佳，所以仍然沒有辦法用來診斷胰臟癌，但目前為止，並沒有任何理想的腫瘤標記可以提昇胰臟癌的早期診斷。
在腸胃道癌症中，有文獻報告指出在胃癌的病人，其血液中adiponectin (ADP)的濃度與他的存活有或疾病分期有關。乳癌，子宮內膜癌都發現他們血液中的ADP濃度與病人腫瘤預後相關。乳癌或大腸癌的病人，當他們出現了癌症的消瘦（cachexia）時，病人血中ADP的濃度會有明顯的變化。 此外，囊狀纖維化之病人其ADP 亦異於正常人。到目前為止，有關於ADP胰臟癌或是慢性胰臟癌的關係則沒有任何報告。至於是否ADP的濃度與癌症的侵襲性或是嚴重度相關，目前尚無任何文獻之報告。
本研究的第三部分有關於血中ADP濃度與慢性胰臟炎和胰臟癌的首次報告。我們發現血中ADP濃度在慢性胰臟炎和胰臟癌的病人都比正常人為高，根據多變相分析，我們評估了年齡，性別，空腹血糖、肝指數；黃疸指數；總膽固醇，三酸甘油脂以及BMI以預測血中ADP濃度與胰臟癌的關係，結果我們發現只有黃疸和BMI是影響血中ADP濃度的獨立危險因子。如果我們將ADP值界定在28，也就是慢性胰臟炎族群的ADP平均值再加上兩個標準差，發現對於診斷胰臟癌的特異性則可大幅提高到97.4﹪。所以這樣的分析顯示出血中ADP界定值提到最高用來區分慢性胰臟炎和胰臟癌的可能性也就越高。在區分慢性胰臟炎或是胰臟癌，比較其AUC之下的面積大小，以ADP較CA19-9為高。這些發現都暗示出血中的ADP具有分辨慢性胰臟炎或是胰臟癌的潛力，尤其是當兩者的CA19-9都上升的情況。

綜而言之，本研究是有關台灣華人慢性胰臟炎基因背景之首次分析，也是首次大規模有關於台灣地區成人慢性胰臟炎的臨床研究。在基因診斷方面對於過去所不瞭解的一些不明原因的慢性胰臟炎，提供初步的基礎。我們也發現與CP是一個與基因相關的疾病。且不同種族以及地域性間的差異很大。經由本論文之完成，我們建立了台灣地區的慢性胰臟炎CFTR之基因分析方式、初步的臨床及基因資料庫。對於不明原因之慢性胰臟炎基因分析，以早期找出帶有突變基因者；而對於早期診斷出帶有突變基因者，則可以提早開始定期之臨床追蹤，給予良好的心理支持，並監測胰臟癌之發生，以期長期的存活率。
根據我們的研究，我們提出了一個台灣地區診斷慢性胰臟炎的建議流程圖(圖28)，在未來將嘗試尋找其他基因變化之可能並分析基因與基因間之交互作用，亦將考慮用動物模式或細胞模式，了解讓基因突變或變異影響胰臟腺細胞或胰管上皮細胞之機轉，希望能更進一步地了解慢性胰臟炎形成的過程與致病機轉。

The aim of the present doctoral thesis is to investigate the clinical and genetic background of chronic pancreatitis in Chinese in Taiwan.

7.1 Introduction and background

7.1.1 Definition of chronic pancreatitis and diagnosis of chronic pancreatitis
Chronic pancreatitis has been defined as a continuing inflammatory disease of the pancreas characterized by irreversible morphologic changes that typically cause pain and/or permanent loss of function. In Western countries, the most common cause of chronic pancreatitis is alcohol abuse. The understanding of the pathogenesis of CP has improved in recent years In recent years, research effort has also focused on the genetic abnormalities that may predispose to CP.
Clinical diagnosis currently depends on identifying defined clinical, functional, morphologic, and histological features .Histopathology remains the golden standard of diagnosis of chronic pancreatitis, especially if the early diagnosis would be made. However, the uneven distribution of fibrosis and the different severity of fibrosis coexist simultaneously, the needle biopsy could not yield good result. Therefore, serrogate criteria for diagnosis of chronic pancreatitis is mandatory.

The present situation descended from the historical limitations in knowledge of etiology, a disproportionate inclusion of patients with decompensated chronic pancreatitis, the complexity of obtaining accurate functional and morphologic data from the pancreas of living patients, and an inability to make an early diagnosis and to follow disease progression. At present, chronic pancreatitis is regarded to an disease of uncertain pathogenesis, unpredictable clinical course, and unclear treatment.

The gold standard
Tissue diagnosis must be the gold standard. Any persistently abnormal inflammatory state or distortion of the normal architecture may serve as strong evidence for chronic pancreatitis, because the correlation with the tissue biopsy “gold standard” is high in the later stages of the disease. Diagnostic pancreatic tissue biopsies are seldom available so that a “gold standard” diagnosis must often be deferred. However, the gold standard must remain a tissue diagnosis. The ideal diagnostic test for chronic pancreatitis should be sensitive, specific, accurate and reliable, widely available, inexpensive, easy to perform, and at no or low risk to the patient. The evaluation of diagnostic methods in current clinical practice must be mindful that a gold standard and definition of chronic pancreatitis remains in question.
For tissue diagnosis,obtaining tissue for evaluation is a primary consideration. Surgical sampling of the pancreas through laparoscopy or laparotomy can safely provide significant amounts of tissue for confirming the diagnosis of chronic pancreatitis. Percutaneous core needle biopsy, guided by either ultrasonography or CT, has been successfully performed for more than 2 decades with a reported complication rate about 1%. However,some etiologies of chronic pancreatitis, including alcohol, hereditary, autoimmune, and “idiopathic” pancreatitis might display patchy abnormalities in pancreatic parenchyma raising the possibility that a single random biopsy may not be diagnostic. Thus, a more sensitive and targeted technique than CT scan or routine transabdominal ultrasound examination is being considered for directed biopsies. EUS-guided biopsies may have similar or better levels of safety as percutaneous biopsy but it has not been perfected owing to possible inadequate specimen and is not widely available.
The key histopathologic features of CP (regardless of etiology) are pancreatic fibrosis, acinar atrophy, chronic inflammation, and distorted and blocked ducts.Additional distinctive histologic features have been described in some forms of CP such as prominent lymphocytic and plasma cell infiltrate in autoimmune pancreatitis.
The diagnosis of chronic pancreatitis can be made by histological or morphologic criteria alone ( calcification in the parenchyma of pancreas) or by a combination of morphologic, functional, and clinical changes. Functional abnormalities alone are not diagnostic of chronic pancreatitis because these tests do not differentiate chronic pancreatitis from pancreatic insufficiency without pancreatitis. However, there are some criteria including abnormal function testing in the diagnostic criteria such as those proposed by Japanese Pancreas Society (JPS).
Furthermore, some distinct type of chronic pancreatitis would not with pancreatic insufficiency . The diagnosis of severe chronic pancreatitis with extensive calcifications (and/or ductal dilation) is simple, even made by a plain abdominal X-rays. The difficulty in diagnosis arises in patients with early, mild, or minimal change pancreatitis, characteristic pancreatic pain alone, patients in whom chronic pancreatitis is being differentiated from a pancreatic malignancy, and in patients with a recent episode of acute pancreatitis.
The correlation between structural and functional impairment of the pancreas in CP is often poor. Patients with severe exocrine insufficiency may have a largely normal pancreatic structure and vice versa. In general, advanced stages of CP may be diagnosed easily by imaging procedures such as ultrasound, computerized tomography (CT), magnetic resonance tomography, and magnetic resonance cholangiopancreatography (MRCP). In contrast, the diagnosis of early disease presents a considerable challenge.The biochemical, structural, and functional parameters used to assist in the diagnosis of CP are described below:
Imaging modalities are commonly used for the evaluation of pancreatic disease( CT, ERP, EUS, and MRI). Chronic pancreatitis with calcifications can also be identified on abdominal x-rays or by transabdominal ultrasound examination, and when present, the diagnosis of chronic pancreatitis can be made.These techniques are used as inexpensive initial screening techniques in some centers.
The abdominal CT scan should be the first test in the evaluation of possible chronic pancreatitis because it is noninvasive, widely available, and has relatively good sensitivity for diagnosing usually late moderate-to-severe chronic pancreatitis. It is useful in identifying most complications of chronic pancreatitis and in identifying pancreatic malignancy. Pancreatitis is diagnosed by CT with the identification of pathognomonic calcifications within the pancreatic ducts or parenchyma, and/or dilated main pancreatic ducts combined with parenchymal atrophy.
Endoscopic retrograde pancreatography(ERP) could detect the morphology of pancreatic duct. However, false positive might be obtained in elder patients who may develop benign pancreatic duct changes without pancreatitis and in patients with recent acute pancreatitis . On the other hand, in patients with chronic pain typically originated from pancreas with a histologic gold standard of chronic pancreatitis may with a normal appearance of pancreatic duct. These conditions decrease the sensitivity and specificity of ERP for diagnosis of chronic pancreatitis. So, most of the scoring system for diagnosis of chronic pancreatitis did not regard the ERP as the essential or independent diagnostic criteria.
The role of endosonography (EUS)for diagnosing early stage CP is not well defined. Several endosonographic features have been noted in patients with chronic pancreatitis such as reduced or increased echogenicity, increased lobulation, and alteration of small and large ducts, have been described. It is accepted that the absence of these criteria reliably rules out CP, whereas the presence of 5 or 6 criteria strongly indicates the diagnosis. The significance of less than 5 criteria, however, is unclear. Beside, a nonhomogeneous echo structure is not a specific sign for CP but also can be seen in the normal pancreas, especially in the elderly.
The pancreas has significant functional reserve, so that it must be damaged significantly before functional loss is clinically recognized. Invasive tests of pancreatic function are the gold standard for determining exocrine pancreatic function. However, pancreatic function testing is not diagnostic of chronic pancreatitis, but rather serves as a sign of chronic pancreatitis and a measure of the severity of injury. Abnormal function test results alone are not diagnostic of chronic pancreatitis in the scoring systems from the Mayo Clinic or Lüneburg Clinic. Although an abnormal secretin test does meet diagnostic criteria for chronic pancreatitis in the JPS criteria, this criteria has been questioned (asia-pacific consensus) .

7.1.2 Classification of chronic pancreatitis
Classification of the various forms of chronic pancreatitis within this definition is likewise challenging. An ideal disease classification system for chronic pancreatitis would be simple, objective, accurate, and relatively noninvasive, incorporating etiology, pathogenesis, structure, function, and clinical status into one overall schema. Although these criteria have never been met, several systems have been advanced. The most widely used classification systems include the Marseille classification of 1963 with revisions in 1984 and 1988 and the Cambridge classification of 1984.
The Marseille system distinguishes acute from chronic pancreatitis :acute pancreatitis must lead to clinical, histologic, and functional resolution of disease once the instigating factor has been removed. Chronic pancreatitis, on the other hand, requires permanent histologic irregularity, often (but not always) associated with persistent clinical and functional impairment. This system relies heavily on the presence of characteristic pain. The two revisions in the original classification attempted to better categorize histopathologic findings to intimate common etiologic pathways leading to disease. The most recent Marseille–Rome classification of 1988 includes more causal factors. However, this system proves more useful in defining chronic pancreatitis than serving as a classification system. The Cambridge classification uses imaging tests to provide a grading system of pancreatic duct. However, these classifications are not satisfactory to distinguish different forms of chronic pancreatitis , not to distinguish patients or the functional abnormalities associated with etiologies. Thus, the Cambridge system proves more useful as a staging system once the diagnosis is made rather than a system for classifying the etiologies of chronic pancreatitis. There are observations emphasize the reality that different disorders causing similar-appearing injury to the pancreas may follow different clinical courses. Thus, clear definitions of chronic pancreatitis, an etiology-based classification system, and functional, structural, and morphologic staging systems are needed. Therefore, a TIGAR-O system was proposed for etiology/classification/risk assessment of chronic pancreatitis: toxic-metabolic causes, idiopathic, genetic, autoimmune, recurrent severe acute pancreatitis–associated chronic pancreatitis, and obstructive chronic pancreatitis.

7.1.3 Clinical features of CP
Abdominal pain is the most vexing clinical problem. Severe pain decreases appetite, thereby contributing to malnutrition and weight loss. The pain is usually epigastric in location (although more diffuse pain in the upper abdomen can occur) and may radiate to the back. Although recurrent (type A) or continuous (type B) pain is considered to be the hallmark of CP, a subgroup of patients may have no pain at all, presenting instead with symptoms of pancreatic insufficiency. In patients with known CP, pain also may result from an acute attack of pancreatitis, from a pancreatic pseudocyst, portal or splenic vein thrombosis, or bile duct obstruction (associated with jaundice). Associated peptic ulcers also may contribute to pain in patients with chronic pancreatitis.
Steatorrhea and weight loss are further important features of CP. Steatorrhea is a symptom of advanced disease and does not occur until pancreatic lipase secretion is reduced to less than 10% of normal. Maldigestion of lipids occurs earlier than that of other nutrients (proteins and carbohydrates). In addition to exocrine insufficiency, diabetes mellitus may develop in the long-term course of the disease. The diabetes is is characterized by destruction of both insulin- and glucagon-producing cells. Co-existing deficiency of glucagon synthesis usually aggravates hypoglycemic situations in pancreatic diabetes..
7.1.4 Epidemiology of chronic pancreatitis
Generally,epidemiological studies are lack in the world. The reported incidence, prevalence, and manifestations of chronic pancreatitis with overt disease underestimate the true spectrum of this disorder. Earlier series from Denmark(Copenhagen), the United States, reported similar incidence of about 4 per 100,000 inhabitants per year. In a study from Japan, 68% of patients with chronic pancreatitis were diagnosed with the use of computed tomography (CT), endoscopic retrograde cholangiopancreatography (ERCP), or other advanced techniques leading to an estimated overall prevalence rate of 45.4 per 100,000 in males and 12.4 per 100,000 in females. Readdressing the epidemiology of chronic pancreatitis using new criteria and better techniques will be important for determining public health care policy and appropriating resources for clinical care and research.
7.1.5 New advance of chronic pancreaitis
More than 50 years ago, it was recognized for the first time that CP may cluster in selected families, suggesting an inherited disease in these patients. The underlying genetic defect, however, remained obscure for more than 4 decades. In 10%–30% of patients suffering from CP, no apparent underlying cause, including heredity, can be identified. Recent research indicates that a significant percentage of these patients with so-called idiopathic CP may also have a genetic basis for their condition.
Several groups located a gene for hereditary pancreatitis on the long arm of chromosome 7 (7q35) by linkage analysis. mutations in the cationic trypsinogen gene, also referred to as serine protease 1 (PRSS1) (OMIM 276000), was identified as a possible underlying defects. R122H appears to be the most common PRSS1 mutation observed worldwide. Subsequent studies have reported other PRSS1 alterations including p.A16V, p.N29I, p.N29T, p.R116C, and p.R122C, as well as several others, in families with suspected hereditary pancreatitis or in patients without a family history. The functional relevance of PRSS1 mutations has been examined by studies using recombinant cationic trypsinogen subjected to site-directed mutagenesis.Thus, gain-of-function mutations leading to enhanced intrapancreatic trypsinogen activation may be the common initiating step of pancreatitis caused by PRSS1 mutations, whereas stabilization of trypsin may be an accessory mechanism.The serine protease inhibitor, Kazal type 1 (SPINK1) (OMIM 167790), also known as pancreatic secretory trypsin inhibitor, is thought to be a potent inhibitor of intrapancreatic trypsin activity.
Genes regulating trypsinogen activation/inactivation and cystic fibrosis transmembrane conductance regulator (CFTR) function have received particular attention. Mutations in these genes are now increasingly recognized for their potential ‘disease modifier’ role in distinct forms of CP such as tropical, and idiopathic pancreatitis.
7.2 Clinical study of chronic pancreatitis in Chinese in Taiwan
There are few reports in clinical study of chronic pancreatitis in Chinese. Most of the studies in chronic pancreatitis originated from western countries or Japan or India in Asia. With the advance and changes of the concept of pathogenesis and classification in chronic pancreatitis, it is necessary and mandatory to understand the current status of chronic pancreatitis in our Chinese.
We reviewed the medical records, morphological/imaging studies and clinical course of each patients with diagnosed as chronic pancreatitis in hospital registry system and also in pathological database between 1994-2005 in National Taiwan University Hospital( a tertiary referred medical center in Taiwan). We validated the accuracy of diagnosis of chronic pancreatitis during this period and also re-analyzed each case according the TIGAR-O system. The demographic data, etiology, and course of different etiology of chronic pancreatitis were collected and analyzed.
There were initially 536 patients coded as chronic pancreatitis in the discharge register system. However, only 330 patients met the criteria of chronic pancreatitis based on histopathological, morphological and clinical criteria. Among them, the etiology, age, gender and increased cased number each year were shown in Figure. On the contrast, there were initially 238 patients coded as chronic pancreatitis in the pathological database. The coding error in pathological database mostly resulted from the wrong given clinical diagnosis of chronic pancreatitis on the pathology requesting from. There were only 126 patients considered chronic pancreatitis after excluding 53 cases with periampullary or any malignancy. In both databases, male gender was predominant. The median age of each type of chronic pancreatitis was similar to previous reports from western countries. The distribution of age also clustered in the middle age. In the idiopathic chronic pancreatitis, there were two peak of onset of age. Idiopathic pancreatitis was the dominant type of chronic pancreatitis in the pathological databases and most of them did not have calcification in the pre-pathologcial imaging diagnosis.
7.3 Genetic analysis of chronic pancreatitis in Chinese in Taiwan
7.3.1 Genetic study of CFTR mutation/polymorphism/haplotype in idiopathic chronic pancreatitis
The cystic fibrosis transmembrane conductance regulator (CFTR) is a cAMP regulated Cl– channel that is expressed in many epithelial tissues. Loss of CFTR (MIM# 602421) gene function due to mutations may causes cystic fibrosis (CF). In addition, there are several other phenotypes associated with CFTR gene mutations, such as congenital bilateral absence of the vas deferens (CBAVD) and idiopathic chronic pancreatitis. More than 1000 different mutations and 200 polymorphisms have already been reported in cystic fibrosis patients (http://www.genet.sickkids.on.ca/cftr/app). Classic cystic fibrosis (CF) is caused by two loss-of-function mutations in the cystic fibrosis transmembrane conductance regulator gene, whereas patients with nonclassic CF have at least one copy of a mutant gene that retains partial function of the CFTR protein. The so-called “mild “ mutations that retain higher CFTR function have been reported to be associated with idiopathic pancreatitis. These reports suggest that different types of mutations in the CFTR gene, causing different degrees of CFTR impairment, can be associated with widely different disease phenotypes. It is now well recognized that the spectrum of CFTR related disease is much broader than previously thought.
One obstacle to comprehensive CFTR studies is the large size of its 27 exon spanning gene. So, most studies that have addressed the role of CFTR mutations in chronic pancreatitis used commercially available screening panels of the 20–30 most common cystic fibrosis causing (rather than pancreatitis causing) CFTR mutations. Furthermore, the geographic distribution of CFTR mutations also varies worldwide.
In addition to mutations, functional polymorphisms have also been detected within the CFTR locus in non-CF individuals that could also potentially result in alterations in CFTR gene expressiony. Haplotype-based analysis has gained increasing attention in evaluating candidate gene in various clinical situations. Merits of haplotype study are more evident in the fine mapping of complex diseases and in identifying genetic variations that influence individual’s susceptibility to diseases and responses to therapy. Therefore, it is advisable to use the haplotype-based approach to address the role of CFTR variants in the risk of idiopathic chronic pancreatitis.
In order to determine whether CFTR mutations, functional polymorphisms and haplotypes affect the risk of developing idiopathic chronic pancreatitis in Chinese, we recruited 78 patients with idiopathic chronic pancreatitis (ICP) and 200 geographically and ethnically matched controls. All patients and control subjects were Chinese an from the same, narrowly confined area in Taiwan. We analyzed the entire coding region and intronic regions of the CFTR gene by denaturing high-performance liquid chromatography (DHPLC), a simple, rapid, non-gel–based, non-fluorescence–based method that uses ion-pair reversed-phase liquid chromatography for detection of DNA variations sensitively and specifically. We also genotyped the common functional SNPs of CFTR by direct sequencing in all subjects and controls. By this means, we could firmly determine that compound heterozygous mutation carriers, as well as heterozygotes with mild and uncommon mutations (previously regarded as unaffected cystic fibrosis carriers) have an increased risk of developing chronic pancreatitis. Furthermore, we analyzed the CFTR haplotype patterns and genotype-phenotype correlations in idiopathic chronic pancreatitis.
Cases and Controls
Patients and controls were recruited at a tertiary referral center (National Taiwan University Hospital) from July 2000 through Dec 2005. All patients and control subjects were Chinese and from the same, narrowly confined area in Taiwan. The control subjects were from the same areas as the cases, were recruited during the same time period from the hospital, and had no history of acute pancreatitis, chronic pancreatitis, diabetes mellitus, pancreatic adenocarcinoma and or apparent biliary or pancreatic diseases. They were also no family history of pancreatitis and pancreatic adenocarcinoma. Chronic pancreatitis was defined as the presence of pancreatic calcifications or histological evidence of chronic pancreatitis. The etiology of chronic pancreatitis was classified with TIGAR-O system. All of Non–insulin-dependent diabetes mellitus was defined as fasting blood glucose >126 mg/dL and/or being administered at least one oral hypoglycemic agent. Patients who reported any known risk factor for pancreatitis, such as a history of nutritive (including alcohol consumption of more than two drinks a day (20 g), biliary, metabolic (such as elevated serum triglycerides, calcium), autoimmune, medication with known pancreatic toxicity, pancreas or periampullary tumors, pancreatic duct anomaly or endocrine disorders, as well as subjects with any evidence of pulmonary diseases or cystic fibrosis, were excluded from the study. Patients identified as mutation carriers in the cationic trypsinogen (PRSS1) gene and serine protease inhibitor Kazal type (SPINK1) gene evaluated by complete sequencing of the coding region were also excluded. There were seventy-eight cases with idiopathic chronic pancreatitis (48 men and 30 women) and 200 control subjects (125 men and 75 women) recruited for analysis. The study was approved by the local institution committee, and the subjects gave their informed consent. The demographic and laboratory data were collected from the medical chart records.
We conducted a comprehensive study involving a cohort of 78 patients with idiopathic chronic pancreatitis as well as a geographically and ethnically matched 200 control subjects. All 27 exons, including flanking intronic regions, were analyzed by DHPLC analysis. The distribution of gender between patients with ICP and controls were not significant.
CFTR mutations
We identified a total number of 22 abnormal CFTR alleles (including T5allele), which amounts to thrice the allele frequency in healthy controls (19 abnormal CFTR alleles in 200 controls; 14.1% vs. 4.8 %, p<0.0001). Among 78 ICP patients, there were 19 patients (19/78, 24.4%) with single abnormal allele and three patients (3/78, 3.8%) with two abnormal alleles. All of our patients were heterozygous for a single CFTR mild/uncommon mutation. All of the identified mutations were mild mutation of CFTR, which might produce a small amount of functional CFTR and was regarded as to be associated with pancreatic phenotype which was concordant with previous report. A total of 20 IVS8-5T (1 homozygote in control group and the others all heterozygotes) and 9 other mutations were identified. The IVS8-5T mutation accounts for 27.2% (6 out of 22) in ICP and 73.7% (14 out of 19) in controls of all identified CFTR mutant alleles. In ICP patients carrying 5T, the mutant allele was all associated with 12 or 13 TG repeats. If we did not include the 5 allele, the mutation rate of CFTR were 10.3 %( 16/156) in ICP and 1.3% 9 5/400) in controls (p<0.0001). The other mutations were identified in heterozygous patients who were all homozygous for 7T in intron 8. These mutations include I556V, G to A 3849+45, N287Y, I125T, E217G, S895N, G1O69R, and Q1352H which have been found in patients with chronic pancreatitis or CBAVD (http://www.genet.sickkids.on.ca).
Genotype and phenotype correlations
The age of onset was younger in patients with ICP who carrying T5 allele (27.5+12.9, p= 0.009). Furthermore, these patients carrying T5 allele were all with TG12 repeat in intron 8. A trend of earlier onset was noted with the increase of number of CFTR mutations but did not reach statistical significance. In subgroup analyses for patients with idiopathic chronic pancreatitis, the age, gender, diabetes mellitus, existence of calcification or pancreatic stones and pseudocyst formation were not significantly associated with the existence or numbers of CFTR mutations. The presence of DM, calcification and pseudocyst were also not associated with the existence of CFTR mutations.
Polymorphisms
Poly T
The 7T was the most common (94.9% in ICP and 96% in controls) and hence the 7T/7T was a dominant genotype in Chinese, similar to Japanese(Fujiki et al., 2004) and Vietnamese(Nam et al., 2005). The T5 (3.6%, 20/556) and T9 alleles (0.7%, 4/556) were much less frequent than the T7 allele. The T6 allele was found with a frequency about 0.1% (1/556). One alleles of 6T was found in normal subjects.
TG repeats

The (TG) 11 and (TG) 12 were dominant TG repeats in Chinese and the ratio was roughly 1:1. Their frequency in chronic pancreatitis was similar to that in normal subjects. The frequency distributions of genotypes of (TG) 11/11, (TG)11/12, and (TG)12/12 were not significantly (p = 0.181) different among normal subjects and patients with idiopathic pancreatitis.

The M470V polymorphism

Our results did not show a significant difference (P=0.316) in genotype and allele frequency distributions of M470V in Taiwanese ICP patients and matched controls (Table ). The frequency distribution of M/M, M/V, and V/V genotypes in chronic pancreatitis was not statistically significant.
5T and its adjacent polymorphic TG repeatsSince the disease penetrance of 5T is affected by its adjacent polymorphic TG repeats, the number of TG dinucleotide repeats in intron 8 of each patient was determined by direct sequencing whatever the DHPLC displayed abnormal profiles. The distribution of 5T/6T/7T/9T, 10/11/12/13TG and M470V alleles were shown in Table. The 5T alleles were not significantly increased in ICP patients (6/156 vs. 14/400; P=0.581). The distribution of TG repeat in each poly T was shown in Table 4. It was found that in all patients carrying 5T, the mutant allele was mostly associated with 12 TG repeats. Allelic variations of 5T–12TG were similarly frequent in the patient group.
Haplotype analysis and association with ICP
Haplotypes were assembled using the genotype data obtained from the 278 tested samples and the haplotype program based on the permutation test as our previous studies. Six loci consisting of five diallelic variants and the Tn(TG)m repeats in intron 8 were analyzed. With 6 loci, there should be 26=64 haplotypes. However, because there were linkage disequilibriums (LDs) in this small region, some haplotypes did not exist or had very low frequencies, and we only listed haplotypes with frequency >0.001. The omnibus haplotype profile test was significant ( 2=26.28184, P=0.008), which indicated the overall haplotype frequency profile difference between cases and controls was significant, and thus there might be some disease-predisposing haplotypes in patients with idiopathic chronic pancreatitis.
In the individual haplotype analyses, we identified haplotypes with significantly higher haplotype frequency in the cases than in the controls at the significance level P<0.05 by permutation tests (the results would not be significant if the stringent Bonferroni correction for probability value were used [ P<0.05/64 for 64 individual haplotype analyses were performed]). All of these significant haplotypes had high haplotype frequencies (>0.01). The 125C /1001+11C/ T7TG11/470V/2694T /4521G haplotype was a dominant haplotype in the Chinese. The 125G /1001+11C/ T7TG12/470M/2694T /4521G haplotype was associated with risk of chronic pancreatitis with a OR 11.3(95% CI: 2.3-54.6) that indicated a large association effect (p=0.008).
The present study is the first comprehensive report on in Chinese with phenotype genotype correlations. The mutations in the CFTR gene ( including 5T allele) account for 14.1% (22/156) of the total alleles and 24.4% (19/78) of patients in our ICP patients, compared to 4.8% (19/400) of the alleles and 9.5%.(19/200) in controls. The CFTR mutation spectrum in the Chinese population was found to be quite different from those observed in the Caucasian populations.
This is the first CFTR study including patients with idiopathic chronic pancreatitis and controls in Chinese by comprehensive analysis. We found that there were marked differences in the mutation spectrum between different ethnic populations in both ICP and controls. Our study has demonstrated that carriers of mild mutations of CFTR and/or a distinct haplotype carry an increased risk of developing idiopathic chronic pancreatitis in Chinese. T5 allele is associated with early onset of idiopathic chronic pancreatitis in our population. To our knowledge, the inheritance pattern of ICP is complex and partially understood. This indicates that the contribution of other factors (such as environmental factors) and interaction with other genetic determinants might affect the disease severity. It remains to be studied and elucidated what the cellular mechanism of mild mutation / functional polymorphisms of CFTR is and how it interact with to other genes to induce chronic pancreatitis. Because of a specific profile of CFTR mutation/haploptype, a population -specific panel should be recommended for targeted populations including idiopathic chronic pancreatitis in Chinese.
7.3.2TNF-alpha promoter polymorphism/haplotype in chronic pancreatitis
Genetic risk factors are attributed to an important role in the pathogenesis of chronic pancreatitis. The genetic basis of chronic pancreatitis is complex. Chronic pancreatitis is a progressive chronic inflammatory disease characterized by irreversible destruction of exocrine pancreatic tissue and extensive fibrosis. Tumor necrosis factor (TNF) , a prototype proinflammatory cytokine, has been implicated as an important pathogenic mediator in a variety of inflammatory diseases. Several biallelic polymorphisms have been described within the TNF-α promoter region upstream of the transcriptional start site. In the past, limited and conflicting data on the associations between TNF- promoter polymorphisms and the pathogenesis of chronic pancreatitis have been reported in western countries
In this study, cases with chronic pancreatitis and controls were recruited consecutively from the National Taiwan University Hospital from July 2000 through June 2003. They were the so-called "Taiwanese" or "Taiwan Chinese." Most of their ancestors moved to Taiwan from southeastern China about 500 years ago. They were not Taiwanese aborigines. Chronic pancreatitis was defined histopathologically or by occurrence of pancreatic parenchymal calcifications demonstrated in imaging studies. All of the patients were negative in trypsinogen gene (PRSS1) and serine protease inhibitor Kazal type 1 (SPINK1) mutations. Patients who had pancreatic adenocarcinoma or any malignancies were also excluded. The etiology of chronic pancreatitis was classified with TIGAR-O system.We genotyped seventy cases (48men and 22women) and 200 control subjects (151 men and 135 women) for five TNF- promoter polymorphisms (-1031, -863, -857, -308 and -238) using direct sequencing. The study was approved by the local institution committee, and the subjects gave their informed consent. The age and gender were not statistically different. All of the study subjects were followed up for at least 3 years and no any malignancy were diagnosed during this period.
The allele frequencies of TNF- promoter -1031C, -863A, -857T, -308A, -238A were as 19%, 19.25%, 26%, 8.25%, and 1.75% respectively and they were consistent with previous reports in the Chinese population. The -863A allele of the TNF- promoter conferred increased risk for chronic pancreatitis (OR=4.949 ; 95% CI 2.678-9.035). In multivariate analysis, the -863A and -1031C were independently associated higher susceptibility of chronic pancreatitis (P<0.0001).
We also determine the haplotypes for chronic pancreatitis risk by the EM-based haplotype frequency estimations and permutation-based hypothesis testing procedures based on previous work in our institution(Tsai et al., 2004). Table1 displays the results of 5-locus estimated haplotype frequency analyses for the TNF- promoter. The omnibus haplotype profile test was highly significant ( 2=58.28461, P=0.001). The TACAG, CACAG, and TACGG haplotypes were associated with a ORs (37.27, 10.97, and 8.50) that indicated a large association effect (p<0.05).
Here we report for the first time associations between TNF- promoter polymorphisms and TNF- promoter haplotype in non-hereditary chronic pancreatitis. Our findings provide the possibility that TNF- promoters are candidate genes for non-hereditary chronic pancreatitis in Chinese. In Taiwanese Chinese, the -863 and -1031 allele of the TNF- promoter were also reported to determine the severity of benign ulceration after Helicobacter pylori infection. Moreover, the -1031/-863/-857 three locus haplotype was associated with higher risk of Alzheimer’s disease in Chinese in Hong Kong. These findings support that the TNF- promoter polymorphism/haplotype is truly associated with some disease entities and phenotypes in our population.
7.4 Differentiating chronic pancreatitis and pancreatic cancer
Chronic pancreatitis is one of the reported risk factor for pancreatic cancer.Pancreatic cancer (ductal adenocarcinoma) is one of the most lethal malignant tumors with poor survival. Most of the patients with pancreatic cancers are diagnosed with advanced diseases. Since chemotherapy and radiotherapy still could not significantly improve the survival of patients with pancreatic cancer, early diagnosis of pancreatic cancer is the key to improve the overall survival in this dismal disease. Even with the tremendous improvement of diagnostic imaging modalities, it is still difficult to distinguish malignant pancreatic tumor from chronic pancreatitis, especially in cases involving inflammatory enlargement of the pancreatic head. Therefore, more and more molecular markers are disclosed to try to distinguish them. The serum marker, sialylated Lewis blood group antigen CA19-9, is widely used in monitoring responses to therapy in pancreatic cancer. However, the role of CA 19-9 as a diagnostic marker of pancreatic cancer is still undetermined(Mann et al., 2000; Piantino et al., 1986). Besides, elevated CA19-9 could also be noted in chronic pancreatitis, cholestasis .On the other hand, false negative results of CA19-9 could be noted in patients do not express Lewis antigens even though in whom with heavy tumor burden of pancreatic cancer(DiMagno et al., 1999; Lamerz, 1999). CA19-9 is also unable to differentiate patients with pancreatic cancer from those with chronic pancreatitis accurately and it is reported that up to 40% of patients with chronic pancreatitis will have increased level of CA19-9. Other tumor markers have also been evaluated, including carcinoembryonic antigen (CEA), CA 242, CA 50, and CA 72-4 in the diagnosis of pancreatic cancer. However, the sensitivity and specificity of these markers appeared to be insufficient for the differentiation of pancreatic carcinoma and chronic pancreatitis.
Up to now, there is no good marker available for screening of high risk population to detect early pancreatic cancer or to differentiate chronic pancreatitis from pancreatic cancer. It is mandatory to search markers to facilitate the diagnosis of pancreatic cancer, especially in risk populations of pancreatic cancer.
Adipose tissue is a now considered to be a genuine endocrine organ producing various adipocytokines, including adiponectin. Plasma adiponectin levels have been shown to decrease in patients with cardiovascular diseases, hypertension, or obesity, type II DM and metabolic syndrome. Interestingly, previous studies have shown serum adiponectin levels are inversely related to BMI and decreased adiponectin level will increase the risk in breast , endometrial cancer and gastric cancer. It is hypothesized that low serum adiponectin levels may underline the association between breast cancer and obesity/insulin resistance. Furthermore, the level of adiponectin was reported to be associated with the tumor aggressiveness in prostate cancer. In recent report, adiponectin was found to be related to cancer cachaxia in breast and colon cancer patients. To our knowledge whether lower adiponectin is associated with more aggressive pancreatic cancer is unknown. In the present study, we examined the association of the serum adiponectin levels in patients with pancreatic cancer and chronic pancreatitis.
A total of 72 patients with pancreatic cancer who were histological proved ductal adenocarcinoma were consecutively collected at the Department of Internal medicine and Surgery, National Taiwan University Hospital, Taiwan between Jan. 1999 and Dec. 2001 were enrolled. None of the pancreatic carcinomas had been treated by chemotherapy or radiation therapy prior to resection. The study was approved by the ethics committee, and informed consent was obtained from each patients. The clinicopathological features of the patients were recorded. Of the 72 patients with pancreatic cancer, 3 were classified as stage I, 8 as stage II, 27 as stage III, and 34 as stage IV, according to the Union International Cancer classification. In addition, we examined several discrete histological parameters, including lymphatic invasion, venous invasion, lymph node metastasis, and tumor markers including CEA and CA19-9 antigens. A fasting morning blood sample was obtained for adiponectin assay after admission. Serum adiponectin concentration was also examined in 39 patients with chronic pancreatitis collected during the same period.
The diagnosis of chronic pancreatitis was confirmed by the presence of at least one of the following criteria: significant changes in ERCP, calcification of the pancreas, or histopathologic confirmation (surgical or biopsy samples). None of the patients with chronic pancreatitis had pancreatic cancer in the follow up period (at least 3 years). A total of 290 control subjects participating in one cardiovascular examination for a health promotion program were included and were confirmed as free from pancreatic cancer and chronic pancreatitis from July to December 2002. These control subjects also showed no abnormality in routine blood tests, urine and stool occult blood tests, chest X-ray examination, and abdominal ultrasonography, and thus were considered to be free of malignancy and chronic pancreatitis. For each patient, written informed consent was obtained.
Anthropometrics and Biomedical Measurements
All blood samples were obtained at fasting early in the morning, and the sera were immediately separated by centrifugation and stored at –80°C until use. Serum adiponectin levels were determined using a commercial ELISA assay with recombinant human Adiponectin as standard (Human Adiponectin ELISA Kit, R&D Systems Inc., Minneapolis MN55413 USA) according to the manufacturer’s instructions.

Serum adiponectin level increased in patients with pancreatic cancer and chronic pancreatitis

The BMI was lower in both the pancreatic cancer and chronic pancreatitis groups than in the control subjects (P<0.0001). The BMI in our study patients with pancreatic cancer and pancreatic cancer were similar.Multivariate analysis was performed to evaluate the role of age, gender, fasting glucose, transaminases, bilirubin, total cholesterol, triglyceride and BMI to predict adiponectin levels in pancreatic cancer patients. Results of the model indicated that only bilirubin and BMI were significant independent predictors of adiponectin levels.

Diagnostic role of adiponectin in pancreatic cancer and chronic pancreatitis

The ROC analysis of ADP and CA19-9 demonstrated the area under the curve of ADP and CA19-9 were performed. The sensitivity, specificity positive predictive value, and negative predictive value of each marker determined at difference cutoff levels were calculated. Increasing the CA 19-9 cut-off value from 37 to 240 lead to increase of the specificity and decrease its sensitivity from 86.5% to 4.1% as the specificity increased from 71.8% to 89.7%. As to the adiponectin, if we use the mean of ADP in chronic pancreatitis (13.7 ng/ml) as the reference cut-off, the sensitivity and the specificity are 70.3% and 74.4% respectively. When the reference limit set at 21.14 ng/ml (mean of ADP in pancreatic cancer patients) was used for ADP, the specificity and sensitivity for discrimination between pancreatic carcinoma and chronic pancreatitis were 29.7% and 92.3%, respectively. Raising the discrimination level for ADP to 28 U/ L (the mean of ADP in chronic pancreatitis plus 2 standard deviations) significantly increased the specificity of ADP to 97.4%.Using the higher cut-off value for ADP allowed ruling out the false positive results for chronic pancreatitis facilitated discrimination of pancreatic adenocarcinoma and chronic pancreatitis.
Adiponectin and clinicopathologic characteristics, staging and prognosis in pancreatic cancers
In our study, there was no correlation between adiponectin level and tumor TNM stage and survival in the pancreatic cancer group. Besides, the CA 19-9 levels did not correlate with TNM stage nor survival, either.

It is the first study to disclose the adiponectin level in pancreatic cancer and chronic pancreatitis. Previous reports in endometrial cancer, and breast cancer both showed an inverse association of cancer risk and the levels of adiponectin. The proposed mechanisms mostly rely on the relationship of obese, insulin resistance or sex hormone status in the cancer risk. The adiponectin is reported to have anti-angiogenic properties both in vivo and in vitro. In our study, the elevated adiponectin is noted in patients with pancreatic cancer after adjust possible factors to influence the adiponectin level including age, gender, BMI , abnormal liver function and jaundice. It is different from the role adiponectin playing in gastric cancer (Goggins, 2005) , prostate cancer and breast cancer. The effects of adiponectin on these cancer cells are currently under investigation.
In our study, the mean of adiponectin level of control subjects, chronic pancreatitis and pancreatic cancer patients were different and an increasing trend among these three groups were noted (p<0.0001).
CA19-9 is the most used traditional serum tumor marker of pancreatic cancer. The sensitivity and specificity to diagnose PC depend on the cut off value we set(Kim et al., 1999). However, the CA19-9 may also increased in patients with CP. In our study, both CA19-9 and adiponectin were elevated in both pancreatic cancer and chronic pancreatitis patients groups than control subjects. Adiponectin outperformed CA19-9 in distinguishing patients with pancreatic cancer from those without pancreatic cancer. Similarly, in the comparison between patients with chronic pancreatitis and those with pancreatic cancer, the adiponectin is still better than CA19-9.These findings suggest that the adiponectin have the potential role as a marker to differentiate the chronic pancreatitis from pancreatic cancer, especially those with elevated CA19-9.
The diagnostic value of ADP for patients with pancreatic carcinoma has never been studied before. In the current study, the results of ADP and CA 19-9 concentrations were measured in two selected patient groups with confirmed pancreatic carcinoma and chronic pancreatitis. Different cut-off levels of ADP and CA 19-9 were considered, and, using ROC curve analysis, the sensitivities for both markers were calculated at predetermined specificity values. Using 28 ng/ml as the reference limit value for ADP and 37 U/mL for CA 19-9 demonstrated an elevation in specificity of the markers reached to 97.4% and 71.8% of pancreatic carcinoma patients, respectively. Based on these results, the upper reference limit for CA 19-9 was kept at 37 U/mL, because increasing its cut-off value did not improve the differential diagnosis between the chronic pancreatitis and pancreatic cancer. On the other hand, using higher ADP levels facilitating discrimination of pancreatic adenocarcinoma and chronic pancreatitis.
The result suggested that ADP has a potential advantage over CA 19-9 because of its significantly higher specificity in pancreatic disease patients, especially in those with elevated CA19-9. The specificity of the high cut-off point for ADP (28ng/ml) seems to offer a better opportunity to distinguish between pancreatic cancer and chronic pancreatitis.

一中文摘要----------------------------------------------------------5
二緒論-------------------------------------------------------------10
2.1 慢性胰臟炎的定義與慢性胰臟炎的診斷------------------------ 10
2.2 慢性胰臟炎的分類-------------------------------------------14
2.3慢性胰臟炎的臨床表現---------------------------------------17
2.4 慢性胰臟炎的流行病學---------------------------------------19
2.5 慢性胰臟炎的新進展與尚未解決的問題-------------------------21
2.6 慢性胰臟炎的基因變化與變異---------------------------------23
2.6.1 CFTR 基因的變異(突變與基因多形性) ------------------ 23
2.6.2 TNF alpha promoter的基因多型性----------------------29
2.7 慢性胰臟炎與胰臟癌的鑑別診斷------------------------------30
2.7.1慢性胰臟炎與胰臟癌-----------------------------------30
2.7.2 鑑別慢性胰臟炎與胰臟癌的生物標記---------------------31
2.8 研究方向假說與目標-----------------------------------------32
三方法-------------------------------------------------------------33
3.1慢性胰臟炎之臨床研究---------------------------------------33
3.2 慢性胰臟炎之基因研究---------------------------------------34
3.2.1 CFTR基因的變異(突變、基因多型性與配分析）和慢性胰臟炎之相關性研究--------------------------------------------40
3.2.2 TNF alpha promoter多型性和慢性胰臟炎之相關性研究41
3.3尋找鑑別慢性胰臟炎與胰臟癌的生物標記-----------------------42
3.3.1 傳統的生物標記:CA19-9 與CEA------------------------ 42
3.3.2脂泌素在慢性胰臟炎與胰臟癌之變化---------------------43
四結果-------------------------------------------------------------44
4.1慢性胰臟炎之臨床研究---------------------------------------44
4.2 慢性胰臟炎之基因研究---------------------------------------46
4.2.1 CFTR 基因的變異(突變,基因多形性,配合子分析)---------- 46
4.2.2 TNF alpha promoter的變異(基因多形性,配合子分析)-48
4.3比較傳統與具有潛能之生物標記鑑別慢性胰臟炎與胰臟癌---------50
五討論-------------------------------------------------------------51
5.1慢性胰臟炎之臨床研究---------------------------------------51
5.2慢性胰臟炎之基因研究---------------------------------------53
5.2.1 CFTR 基因的變異--------------------------------------53
5.2.2 TNF alpha promoter的變異-------------------------58
5.3鑑別慢性胰臟炎與胰臟癌之生物標記---------------------------60

六展望
6.1 慢性胰臟炎之基因診斷與基因基因間交互作用------------------62
6.2 慢性胰臟炎之早期診斷--------------------------------------64
6.3 基因檢測--------------------------------------------------66
七論文英文簡述----------------------------------------------------67
八參考文獻--------------------------------------------------------85
九圖表------------------------------------------------------------95
十附錄-----------------------------------------------------------146

Copenhagen pancreatitis study. An interim report from a prospective epidemiological multicentre study. Scand J Gastroenterol 1981 16, 305-312.
Alazmi, W. M., Fogel, E. L., Schmidt, S., Watkins, J. L., McHenry, L., Sherman, S., and Lehman, G. A. ERCP findings in idiopathic pancreatitis: patients who are cystic fibrosis gene positive and negative. Gastrointest Endosc 2006 63, 234-239.
Ammann, R. W., Heitz, P. U., and Kloppel, G. Course of alcoholic chronic pancreatitis: a prospective clinicomorphological long-term study. Gastroenterology 1996 111, 224-231.
Ammann, R. W., and Muellhaupt, B. The natural history of pain in alcoholic chronic pancreatitis. Gastroenterology 1999 116, 1132-1140.
Arduino, C., Gallo, M., Brusco, A., Garnerone, S., Piana, M. R., Di Maggio, S., Gerbino Promis, G., Ferrone, M., Angeli, A., and Gaia, E. Polyvariant mutant CFTR genes in patients with chronic pancreatitis. Clin Genet 1999 56, 400-404.
Arvanitakis, M., Van Laethem, J. L., Parma, J., De Maertelaer, V., Delhaye, M., and Deviere, J. Predictive factors for pancreatic cancer in patients with chronic pancreatitis in association with K-ras gene mutation. Endoscopy 2004 36, 535-542.
Barman, K. K., Premalatha, G., and Mohan, V. Tropical chronic pancreatitis. Postgrad Med J 2003 79, 606-615.
Beranek, H., Teich, N., Witt, H., Schulz, H. U., Mossner, J., and Keim, V. Analysis of tumour necrosis factor alpha and interleukin 10 promotor variants in patients with chronic pancreatitis. Eur J Gastroenterol Hepatol 2003 15, 1223-1227.
Berrington de Gonzalez, A., Sweetland, S., and Spencer, E. A meta-analysis of obesity and the risk of pancreatic cancer. Br J Cancer 2003 89, 519-523.
Bhatia, E., Choudhuri, G., Sikora, S. S., Landt, O., Kage, A., Becker, M., and Witt, H. Tropical calcific pancreatitis: strong association with SPINK1 trypsin inhibitor mutations. Gastroenterology 2002 123, 1020-1025.
Bombieri, C., Giorgi, S., Carles, S., de Cid, R., Belpinati, F., Tandoi, C., Pallares-Ruiz, N., Lazaro, C., Ciminelli, B. M., Romey, M. C., Casals, T., Pompei, F., Gandini, G., Claustres, M., Estivill, X., Pignatti, P. F., and Modiano, G. A new approach for identifying non-pathogenic mutations. An analysis of the cystic fibrosis transmembrane regulator gene in normal individuals. Hum Genet 2000 106, 172-178.
Braganza, J. M., Hunt, L. P., and Warwick, F. Relationship between pancreatic exocrine function and ductal morphology in chronic pancreatitis. Gastroenterology 1982 82, 1341-1347.
Brakenhielm, E., Veitonmaki, N., Cao, R., Kihara, S., Matsuzawa, Y., Zhivotovsky, B., Funahashi, T., and Cao, Y. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A 2004 101, 2476-2481.
Buratti, E., and Baralle, F. E. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J Biol Chem 2001 276, 36337-36343.
Cantor, M. J., Nickerson, P., and Bernstein, C. N. The role of cytokine gene polymorphisms in determining disease susceptibility and phenotype in inflammatory bowel disease. Am J Gastroenterol 2005 100, 1134-1142.
Chari, S. T., and Singer, M. V. The problem of classification and staging of chronic pancreatitis. Proposals based on current knowledge of its natural history. Scand J Gastroenterol 1994 29, 949-960.
Chen, D. C., Chung, Y. F., Yeh, Y. T., Chaung, H. C., Kuo, F. C., Fu, O. Y., Chen, H. Y., Hou, M. F., and Yuan, S. S. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett 2006 237, 109-114.
Clain, J. E., and Pearson, R. K. Diagnosis of chronic pancreatitis. Is a gold standard necessary? Surg Clin North Am 1999 79, 829-845.
Cohn, J. A., Friedman, K. J., Noone, P. G., Knowles, M. R., Silverman, L. M., and Jowell, P. S. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med 1998 339, 653-658.
Cohn, J. A., Neoptolemos, J. P., Feng, J., Yan, J., Jiang, Z., Greenhalf, W., McFaul, C., Mountford, R., and Sommer, S. S. Increased risk of idiopathic chronic pancreatitis in cystic fibrosis carriers. Hum Mutat 2005 26, 303-307.
Colombo, C., Apostolo, M. G., Ferrari, M., Seia, M., Genoni, S., Giunta, A., and Sereni, L. P. Analysis of risk factors for the development of liver disease associated with cystic fibrosis. J Pediatr 1994 124, 393-399.
Comfort, M. W., and Steinberg, A. G. Pedigree of a family with hereditary chronic relapsing pancreatitis. Gastroenterology 1952 21, 54-63.
Cuppens, H., Lin, W., Jaspers, M., Costes, B., Teng, H., Vankeerberghen, A., Jorissen, M., Droogmans, G., Reynaert, I., Goossens, M., Nilius, B., and Cassiman, J. J. Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J Clin Invest 1998 101, 487-496.
Dal Maso, L., Augustin, L. S., Karalis, A., Talamini, R., Franceschi, S., Trichopoulos, D., Mantzoros, C. S., and La Vecchia, C. Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 2004 89, 1160-1163.
DiMagno, E. P., Go, V. L., and Summerskill, W. H. Relations between pancreatic enzyme ouputs and malabsorption in severe pancreatic insufficiency. N Engl J Med 1973 288, 813-815.
DiMagno, E. P., Reber, H. A., and Tempero, M. A. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology 1999 117, 1464-1484.
Durno, C., Corey, M., Zielenski, J., Tullis, E., Tsui, L. C., and Durie, P. Genotype and phenotype correlations in patients with cystic fibrosis and pancreatitis. Gastroenterology 2002 123, 1857-1864.
Ectors, N., Maillet, B., Aerts, R., Geboes, K., Donner, A., Borchard, F., Lankisch, P., Stolte, M., Luttges, J., Kremer, B., and Kloppel, G. Non-alcoholic duct destructive chronic pancreatitis. Gut 1997 41, 263-268.
El-Omar, E. M., Rabkin, C. S., Gammon, M. D., Vaughan, T. L., Risch, H. A., Schoenberg, J. B., Stanford, J. L., Mayne, S. T., Goedert, J., Blot, W. J., Fraumeni, J. F., Jr., and Chow, W. H. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003 124, 1193-1201.
Etemad, B., and Whitcomb, D. C. Chronic pancreatitis: diagnosis, classification, and new genetic developments. Gastroenterology 2001 120, 682-707.
Finkelberg, D. L., Sahani, D., Deshpande, V., and Brugge, W. R. Autoimmune pancreatitis. N Engl J Med 2006 355, 2670-2676.
Fujiki, K., Ishiguro, H., Ko, S. B., Mizuno, N., Suzuki, Y., Takemura, T., Yamamoto, A., Yoshikawa, T., Kitagawa, M., Hayakawa, T., Sakai, Y., Takayama, T., Saito, M., Kondo, T., and Naruse, S. Genetic evidence for CFTR dysfunction in Japanese: background for chronic pancreatitis. J Med Genet 2004 41, e55.
Ghanem, N., Costes, B., Girodon, E., Martin, J., Fanen, P., and Goossens, M. Identification of eight mutations and three sequence variations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics 1994 21, 434-436.
Goggins, M. Molecular markers of early pancreatic cancer. J Clin Oncol 2005 23, 4524-4531.
Goh, K. L. Chronic pancreatitis: aetiology, epidemiology and clinical presentation. Med J Malaysia 2005 60 Suppl B, 94-98.
Goktas, S., Yilmaz, M. I., Caglar, K., Sonmez, A., Kilic, S., and Bedir, S. Prostate cancer and adiponectin. Urology 2005 65, 1168-1172.
Gonzalez-Quintela, A., Dominguez-Santalla, M. J., Loidi, L., Quinteiro, C., and Perez, L. F. Relation of tumor necrosis factor (TNF) gene polymorphisms with serum concentrations and in vitro production of TNF-alpha and interleukin-8 in heavy drinkers. Alcohol 2004 34, 273-277.
Groman, J. D., Hefferon, T. W., Casals, T., Bassas, L., Estivill, X., Des Georges, M., Guittard, C., Koudova, M., Fallin, M. D., Nemeth, K., Fekete, G., Kadasi, L., Friedman, K., Schwarz, M., Bombieri, C., Pignatti, P. F., Kanavakis, E., Tzetis, M., Schwartz, M., Novelli, G., D''Apice, M. R., Sobczynska-Tomaszewska, A., Bal, J., Stuhrmann, M., Macek, M., Jr., Claustres, M., and Cutting, G. R. Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. Am J Hum Genet 2004 74, 176-179.
Haber, P. S., Keogh, G. W., Apte, M. V., Moran, C. S., Stewart, N. L., Crawford, D. H., Pirola, R. C., McCaughan, G. W., Ramm, G. A., and Wilson, J. S. Activation of pancreatic stellate cells in human and experimental pancreatic fibrosis. Am J Pathol 1999 155, 1087-1095.
Haglund, C., Roberts, P. J., Kuusela, P., Scheinin, T. M., Makela, O., and Jalanko, H. Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer 1986 53, 197-202.
Hamosh, A., Rosenstein, B. J., and Cutting, G. R. CFTR nonsense mutations G542X and W1282X associated with severe reduction of CFTR mRNA in nasal epithelial cells. Hum Mol Genet 1992 1, 542-544.
Harlozinska-Szmyrka, A., and Strutynska-Karpinska, M. The diagnostic dilemmas in discrimination between pancreatic carcinoma and chronic pancreatitis. Gut 2004 53, 469-470.
Hefferon, T. W., Groman, J. D., Yurk, C. E., and Cutting, G. R. A variable dinucleotide repeat in the CFTR gene contributes to phenotype diversity by forming RNA secondary structures that alter splicing. Proc Natl Acad Sci U S A 2004 101, 3504-3509.
Hellmig, S., Fischbach, W., Goebeler-Kolve, M. E., Folsch, U. R., Hampe, J., and Schreiber, S. A functional promotor polymorphism of TNF-alpha is associated with primary gastric B-Cell lymphoma. Am J Gastroenterol 2005 100, 2644-2649.
Higuchi, T., Seki, N., Kamizono, S., Yamada, A., Kimura, A., Kato, H., and Itoh, K. Polymorphism of the 5''-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens 1998 51, 605-612.
Homma, T., Harada, H., and Koizumi, M. Diagnostic criteria for chronic pancreatitis by the Japan Pancreas Society. Pancreas 1997 15, 14-15.
Hotta, K., Funahashi, T., Arita, Y., Takahashi, M., Matsuda, M., Okamoto, Y., Iwahashi, H., Kuriyama, H., Ouchi, N., Maeda, K., Nishida, M., Kihara, S., Sakai, N., Nakajima, T., Hasegawa, K., Muraguchi, M., Ohmoto, Y., Nakamura, T., Yamashita, S., Hanafusa, T., and Matsuzawa, Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000 20, 1595-1599.
Ishikawa, M., Kitayama, J., Kazama, S., Hiramatsu, T., Hatano, K., and Nagawa, H. Plasma adiponectin and gastric cancer. Clin Cancer Res 2005 11, 466-472.
Kadowaki, T., and Yamauchi, T. Adiponectin and adiponectin receptors. Endocr Rev 2005 26, 439-451.
Kerem, B., Rommens, J. M., Buchanan, J. A., Markiewicz, D., Cox, T. K., Chakravarti, A., Buchwald, M., and Tsui, L. C. Identification of the cystic fibrosis gene: genetic analysis. Science 1989 245, 1073-1080.
Kim, H. J., Kim, M. H., Myung, S. J., Lim, B. C., Park, E. T., Yoo, K. S., Seo, D. W., Lee, S. K., and Min, Y. I. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol 1999 94, 1941-1946.
Kloppel, G., and Maillet, B. Pseudocysts in chronic pancreatitis: a morphological analysis of 57 resection specimens and 9 autopsy pancreata. Pancreas 1991 6, 266-274.
Kloppel, G., and Maillet, B. Pathology of acute and chronic pancreatitis. Pancreas 1993 8, 659-670.
Koopmann, J., Rosenzweig, C. N., Zhang, Z., Canto, M. I., Brown, D. A., Hunter, M., Yeo, C., Chan, D. W., Breit, S. N., and Goggins, M. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 2006 12, 442-446.
Kumada, M., Kihara, S., Sumitsuji, S., Kawamoto, T., Matsumoto, S., Ouchi, N., Arita, Y., Okamoto, Y., Shimomura, I., Hiraoka, H., Nakamura, T., Funahashi, T., and Matsuzawa, Y. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003 23, 85-89.
Lamerz, R. Role of tumour markers, cytogenetics. Ann Oncol 1999 10 Suppl 4, 145-149.
Layer, P., Yamamoto, H., Kalthoff, L., Clain, J. E., Bakken, L. J., and DiMagno, E. P. The different courses of early- and late-onset idiopathic and alcoholic chronic pancreatitis. Gastroenterology 1994 107, 1481-1487.
Lee, J. H., Choi, J. H., Namkung, W., Hanrahan, J. W., Chang, J., Song, S. Y., Park, S. W., Kim, D. S., Yoon, J. H., Suh, Y., Jang, I. J., Nam, J. H., Kim, S. J., Cho, M. O., Lee, J. E., Kim, K. H., and Lee, M. G. A haplotype-based molecular analysis of CFTR mutations associated with respiratory and pancreatic diseases. Hum Mol Genet 2003 12, 2321-2332.
Li, D., Xie, K., Wolff, R., and Abbruzzese, J. L. Pancreatic cancer. Lancet 2004 363, 1049-1057.
Lin, Y., Tamakoshi, A., Matsuno, S., Takeda, K., Hayakawa, T., Kitagawa, M., Naruse, S., Kawamura, T., Wakai, K., Aoki, R., Kojima, M., and Ohno, Y. Nationwide epidemiological survey of chronic pancreatitis in Japan. J Gastroenterol 2000 35, 136-141.
Lowenfels, A. B., and Maisonneuve, P. Risk factors for pancreatic cancer. J Cell Biochem 2005 95, 649-656.
Lu, C. C., Sheu, B. S., Chen, T. W., Yang, H. B., Hung, K. H., Kao, A. W., Chuang, C. H., and Wu, J. J. Host TNF-alpha-1031 and -863 promoter single nucleotide polymorphisms determine the risk of benign ulceration after H. pylori infection. Am J Gastroenterol 2005 100, 1274-1282.
Ma, S. L., Tang, N. L., Lam, L. C., and Chiu, H. F. Association between tumor necrosis factor-alpha promoter polymorphism and Alzheimer''s disease. Neurology 2004 62, 307-309.
Mahurkar, S., Idris, M. M., Reddy, D. N., Bhaskar, S., Rao, G. V., Thomas, V., Singh, L., and Chandak, G. R. Association of cathepsin B gene polymorphisms with tropical calcific pancreatitis. Gut 2006 55, 1270-1275.
Maire, F., Bienvenu, T., Ngukam, A., Hammel, P., Ruszniewski, P., and Levy, P. [Frequency of CFTR gene mutations in idiopathic pancreatitis]. Gastroenterol Clin Biol 2003 27, 398-402.
Malfertheiner, P., and Buchler, M. Correlation of imaging and function in chronic pancreatitis. Radiol Clin North Am 1989 27, 51-64.
Malka, D., Hammel, P., Maire, F., Rufat, P., Madeira, I., Pessione, F., Levy, P., and Ruszniewski, P. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut 2002 51, 849-852.
Mann, D. V., Edwards, R., Ho, S., Lau, W. Y., and Glazer, G. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000 26, 474-479.
Mantzoros, C., Petridou, E., Dessypris, N., Chavelas, C., Dalamaga, M., Alexe, D. M., Papadiamantis, Y., Markopoulos, C., Spanos, E., Chrousos, G., and Trichopoulos, D. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004 89, 1102-1107.
Mews, P., Phillips, P., Fahmy, R., Korsten, M., Pirola, R., Wilson, J., and Apte, M. Pancreatic stellate cells respond to inflammatory cytokines: potential role in chronic pancreatitis. Gut 2002 50, 535-541.
Miyoshi, Y., Funahashi, T., Kihara, S., Taguchi, T., Tamaki, Y., Matsuzawa, Y., and Noguchi, S. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 2003 9, 5699-5704.
Mohan, V., Ramachandran, A., Vijay Kumar, G., Snehalatha, C., and Viswanathan, M. Insulin resistance in Fibrocalculous (tropical) pancreatic diabetes. Horm Metab Res 1988 20, 746-748.
Moriconi, N., Kraenzlin, M., Muller, B., Keller, U., Nusbaumer, C. P., Stohr, S., Tamm, M., and Puder, J. J. Body composition and adiponectin serum concentrations in adult patients with cystic fibrosis. J Clin Endocrinol Metab 2006 91, 1586-1590.
Nadra, I., Mason, J. C., Philippidis, P., Florey, O., Smythe, C. D., McCarthy, G. M., Landis, R. C., and Haskard, D. O. Proinflammatory activation of macrophages by basic calcium phosphate crystals via protein kinase C and MAP kinase pathways: a vicious cycle of inflammation and arterial calcification? Circ Res 2005 96, 1248-1256.
Nagai, H., and Ohtsubo, K. Pancreatic lithiasis in the aged. Its clinicopathology and pathogenesis. Gastroenterology 1984 86, 331-338.
Nam, M. H., Hijikata, M., Tuan le, A., Lien, L. T., Shojima, J., Horie, T., Nakata, K., Matsushita, I., Ohashi, J., Tokunaga, K., and Keicho, N. Variations of the CFTR gene in the Hanoi-Vietnamese. Am J Med Genet A 2005 136, 249-253.
Negoro, K., Kinouchi, Y., Hiwatashi, N., Takahashi, S., Takagi, S., Satoh, J., Shimosegawa, T., and Toyota, T. Crohn''s disease is associated with novel polymorphisms in the 5''-flanking region of the tumor necrosis factor gene. Gastroenterology 1999 117, 1062-1068.
Ngiam, N. S., Chong, S. S., Shek, L. P., Goh, D. L., Ong, K. C., Chng, S. Y., Yeo, G. H., and Goh, D. Y. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in Asians with chronic pulmonary disease: a pilot study. J Cyst Fibros 2006 5, 159-164.
Oh, S. W., Yoon, Y. S., and Shin, S. A. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol 2005 23, 4742-4754.
Oppenheimer, E. H., and Esterly, J. R. Pathology of cystic fibrosis review of the literature and comparison with 146 autopsied cases. Perspect Pediatr Pathol 1975 2, 241-278.
Pannacciulli, N., Vettor, R., Milan, G., Granzotto, M., Catucci, A., Federspil, G., De Giacomo, P., Giorgino, R., and De Pergola, G. Anorexia nervosa is characterized by increased adiponectin plasma levels and reduced nonoxidative glucose metabolism. J Clin Endocrinol Metab 2003 88, 1748-1752.
Petridou, E., Mantzoros, C., Dessypris, N., Koukoulomatis, P., Addy, C., Voulgaris, Z., Chrousos, G., and Trichopoulos, D. Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. J Clin Endocrinol Metab 2003 88, 993-997.
Piantino, P., Andriulli, A., Gindro, T., Pecchio, F., Masoero, G., Cavallini, G., Naccarato, R., and Dobrilla, G. CA 19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases. Am J Gastroenterol 1986 81, 436-439.
Rajan, E., Clain, J. E., Levy, M. J., Norton, I. D., Wang, K. K., Wiersema, M. J., Vazquez-Sequeiros, E., Nelson, B. J., Jondal, M. L., Kendall, R. K., Harmsen, W. S., and Zinsmeister, A. R. Age-related changes in the pancreas identified by EUS: a prospective evaluation. Gastrointest Endosc 2005 61, 401-406.
Riela, A., Zinsmeister, A. R., Melton, L. J., 3rd, Weiland, L. H., and DiMagno, E. P. Increasing incidence of pancreatic cancer among women in Olmsted County, Minnesota, 1940 through 1988. Mayo Clin Proc 1992 67, 839-845.
Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J. L., and et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989 245, 1066-1073.
Rommens, J. M., Iannuzzi, M. C., Kerem, B., Drumm, M. L., Melmer, G., Dean, M., Rozmahel, R., Cole, J. L., Kennedy, D., Hidaka, N., and et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989 245, 1059-1065.
Rowntree, R., and Harris, A. DNA polymorphisms in potential regulatory elements of the CFTR gene alter transcription factor binding. Hum Genet 2002 111, 66-74.
Rowntree, R. K., and Harris, A. The phenotypic consequences of CFTR mutations. Ann Hum Genet 2003 67, 471-485.
Sarles, H. Not Available. Arch Mal Appar Dig Mal Nutr 1956 45, 7-24.
Sarles, H., Adler, G., Dani, R., Frey, C., Gullo, L., Harada, H., Martin, E., Norohna, M., and Scuro, L. A. The pancreatitis classification of Marseilles-Rome 1988. Scand J Gastroenterol 1989 24, 641-642.
Sarner, M., and Cotton, P. B. Classification of pancreatitis. Gut 1984 25, 756-759.
Schmitt-Grohe, S., Stuber, F., Book, M., Bargon, J., Wagner, T. O., Naujoks, C., Schubert, R., Lentze, M. J., and Zielen, S. TNF-alpha promoter polymorphism in relation to TNF-alpha production and clinical status in cystic fibrosis. Lung 2006 184, 99-104.
Schneider, A., Barmada, M. M., Slivka, A., Martin, J. A., and Whitcomb, D. C. Analysis of tumor necrosis factor-alpha, transforming growth factor-beta 1, interleukin-10, and interferon-gamma polymorphisms in patients with alcoholic chronic pancreatitis. Alcohol 2004 32, 19-24.
Schneider, A., Pogue-Geile, K., Barmada, M. M., Myers-Fong, E., Thompson, B. S., and Whitcomb, D. C. Hereditary, familial, and idiopathic chronic pancreatitis are not associated with polymorphisms in the tumor necrosis factor alpha (TNF-alpha) promoter region or the TNF receptor 1 (TNFR1) gene. Genet Med 2003 5, 120-125.
Sharer, N., Schwarz, M., Malone, G., Howarth, A., Painter, J., Super, M., and Braganza, J. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med 1998 339, 645-652.
Singer, M. V., Gyr, K., and Sarles, H. Revised classification of pancreatitis. Report of the Second International Symposium on the Classification of Pancreatitis in Marseille, France, March 28-30, 1984. Gastroenterology 1985 89, 683-685.
Soga, Y., Nishimura, F., Ohyama, H., Maeda, H., Takashiba, S., and Murayama, Y. Tumor necrosis factor-alpha gene (TNF-alpha) -1031/-863, -857 single-nucleotide polymorphisms (SNPs) are associated with severe adult periodontitis in Japanese. J Clin Periodontol 2003 30, 524-531.
Steiner, B., Truninger, K., Sanz, J., Schaller, A., and Gallati, S. The role of common single-nucleotide polymorphisms on exon 9 and exon 12 skipping in nonmutated CFTR alleles. Hum Mutat 2004 24, 120-129.
Stevens, T., Conwell, D. L., and Zuccaro, G. Pathogenesis of chronic pancreatitis: an evidence-based review of past theories and recent developments. Am J Gastroenterol 2004 99, 2256-2270.
Tacke, F., Wustefeld, T., Horn, R., Luedde, T., Srinivas Rao, A., Manns, M. P., Trautwein, C., and Brabant, G. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol 2005 42, 666-673.
Tandon, R. K., Sato, N., and Garg, P. K. Chronic pancreatitis: Asia-Pacific consensus report. J Gastroenterol Hepatol 2002 17, 508-518.
Tanner, M. S., and Taylor, C. J. Liver disease in cystic fibrosis. Arch Dis Child 1995 72, 281-284.
Tintut, Y., Patel, J., Parhami, F., and Demer, L. L. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 2000 102, 2636-2642.
Trujillo, M. E., and Scherer, P. E. Adiponectin--journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005 257, 167-175.
Tsai, C. T., Lai, L. P., Lin, J. L., Chiang, F. T., Hwang, J. J., Ritchie, M. D., Moore, J. H., Hsu, K. L., Tseng, C. D., Liau, C. S., and Tseng, Y. Z. Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation 2004 109, 1640-1646.
Tsuchiya, N., Tokushige, K., Yamaguchi, N., Hasegawa, K., Hashimoto, E., Yamauchi, K., and Shiratori, K. Influence of TNF gene polymorphism in patients with acute and fulminant hepatitis. J Gastroenterol 2004 39, 859-866.
Valenti, L., Pulixi, E., Fracanzani, A. L., Dongiovanni, P., Maggioni, M., Orsatti, A., Gianni, C., and Fargion, S. TNFalpha genotype affects TNFalpha release, insulin sensitivity and the severity of liver disease in HCV chronic hepatitis. J Hepatol 2005 43, 944-950.
Walsh, T. N., Rode, J., Theis, B. A., and Russell, R. C. Minimal change chronic pancreatitis. Gut 1992 33, 1566-1571.
Weiss, F. U., Simon, P., Bogdanova, N., Mayerle, J., Dworniczak, B., Horst, J., and Lerch, M. M. Complete cystic fibrosis transmembrane conductance regulator gene sequencing in patients with idiopathic chronic pancreatitis and controls. Gut 2005 54, 1456-1460.
Whitcomb, D. C., Gorry, M. C., Preston, R. A., Furey, W., Sossenheimer, M. J., Ulrich, C. D., Martin, S. P., Gates, L. K., Jr., Amann, S. T., Toskes, P. P., Liddle, R., McGrath, K., Uomo, G., Post, J. C., and Ehrlich, G. D. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet 1996 14, 141-145.
Wiersema, M. J., Hawes, R. H., Lehman, G. A., Kochman, M. L., Sherman, S., and Kopecky, K. K. Prospective evaluation of endoscopic ultrasonography and endoscopic retrograde cholangiopancreatography in patients with chronic abdominal pain of suspected pancreatic origin. Endoscopy 1993 25, 555-564.
Wilson, A. G., Symons, J. A., McDowell, T. L., McDevitt, H. O., and Duff, G. W. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A 1997 94, 3195-3199.
Witt, H., Apte, M. V., Keim, V., and Wilson, J. S. Chronic pancreatitis: challenges and advances in pathogenesis, genetics, diagnosis, and therapy. Gastroenterology 2007 132, 1557-1573.
Witt, H., Luck, W., Hennies, H. C., Classen, M., Kage, A., Lass, U., Landt, O., and Becker, M. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet 2000 25, 213-216.
Wojnarowski, C., Frischer, T., Hofbauer, E., Grabner, C., Mosgoeller, W., Eichler, I., and Ziesche, R. Cytokine expression in bronchial biopsies of cystic fibrosis patients with and without acute exacerbation. Eur Respir J 1999 14, 1136-1144.
Wolf, I., Sadetzki, S., Kanety, H., Kundel, Y., Pariente, C., Epstein, N., Oberman, B., Catane, R., Kaufman, B., and Shimon, I. Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer 2006 106, 966-973.
Wu, C. C., Alper, O. M., Lu, J. F., Wang, S. P., Guo, L., Chiang, H. S., and Wong, L. J. Mutation spectrum of the CFTR gene in Taiwanese patients with congenital bilateral absence of the vas deferens. Hum Reprod 2005 20, 2470-2475.
Xie, M. J., Motoo, Y., Su, S. B., and Sawabu, N. Expression of tumor necrosis factor-alpha, interleukin-6, and interferon-gamma in spontaneous chronic pancreatitis in the WBN/Kob rat. Pancreas 2001 22, 400-408.
Yang, W. S., and Chuang, L. M. Human genetics of adiponectin in the metabolic syndrome. J Mol Med 2006 84, 112-121.
Yang, W. S., Lee, W. J., Funahashi, T., Tanaka, S., Matsuzawa, Y., Chao, C. L., Chen, C. L., Tai, T. Y., and Chuang, L. M. Plasma adiponectin levels in overweight and obese Asians. Obes Res 2002 10, 1104-1110.
Zielenski, J., and Tsui, L. C. Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet 1995 29, 777-807.